November 2, 2007
Bausch & Lomb Currently Faces 573 Product Liability Lawsuits Stemming From Eye Infections Caused by ReNu MoisturLoc Contact Lens Solution
Analysis: With the recent buyout of Bausch & Lomb (B&L) by Warburg Pincus, it would seem that they are on the recovery trail. But, this report definitely indicates that it will be quite some time, and will require quite a lot of money, before their ReNu MoisturLoc problems are resolved.
I found it interesting that the article stated that the CDC directly named the poor disinfecting properties of the MoisturLoc solution, and not the questionable contact lens hygiene habits of the users, as the cause of the Fusarium outbreak. I've read reports from B&L stating that poor contact lens hygiene was just as responsible for the outbreak as the solution itself. Also, I never realized also that the South Carolina plant that produced the MoisturLoc had been cited by the FDA for prior quality control problems. Who knows, maybe the Fusarium outbreak could have been avoided if someone at B&L had fixed these quality control problems.
On a personal note, B&L continues to be my least prescribed company, as far as contact lenses and contact lens solutions go. I've talked to our rep. a couple times trying to get some contact lens trial sets in my office, but he continue to insist they will only send sets to those who sell a large volume of their contacts. My argument that, "If I don't have any trial lenses, how am I going to sell your lenses?" didn't convince him. Somehow Vistakon and Coopervision both take this argument to heart, and send me as many trial sets as I ask for. The B&L rep. also told me that he couldn't send me any contact lens solution (ReNu Multiplus) because they didn't have any to give me. They were back-ordered because of the increased demand after AMO's Complete had been recalled. This is their big chance to gain a big chunk of their lost market share, and they're dropping the ball.
So, 573 state and federal lawsuits to date, many years in court, potentially over $1 billion, and at least one unsatisfied Optometrist... B&L has a tough road ahead.
Report a Concern
More GLG News in
Healthcare
ADAGIO Trial Results Show Teva's AZILECT(R) 1 Mg Tablets Slow Progression Of Parkinson's Disease
www.medicalnewstoday.com
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
www.therapeuticsdaily.com
Expanding Circle of Inhibition: Small-Molecule Inhibitors of Bcl-2 as Anticancer Cell and Antiangiogenic Agents
jco.ascopubs.org
ACE Inhibitor May Ease Cardiac Risks in Marfan's Syndrome
www.medpagetoday.com
Healthways' Guidance Not So Healthy
www.forbes.com
Azilect
September 2, 2008
Byetta Saves Lives
September 2, 2008
The Devil Is in the Details
September 1, 2008
Dangers of Methadone Usage
August 28, 2008
Healthways A Market Downturn and Results
August 26, 2008

